Visceral Leishmaniasis in Bolivia: Current Status.

Introduction: In Bolivia, before 1982 there were no records of visceral leishmaniasis (VL) cases that would allow us to review and describe the temporospatial occurrence of VL by ecoregions in provinces and departments of Bolivia to evaluate its impact on public health, risk of outbreaks, or dispersion.

Methods: This update on VL in Bolivia is based on research, reviews, and retrospective literature analyses of online data and libraries and institutional reports, from 1939 to the present.

Results: In Bolivia, 56 cases of VL have been reported.

[Leishmaniasis en Bolivia. Comprehensive review and current status in Tarija, in the border with Argentina].

Introduction: In the department of Tarija in the Bolivian-Argentine border, human cases with ulcers on uncovered parts of the skin plus clinical and epidemiological characteristics related to leishmaniasis were reported for the first time in 1997. Objective: To describe and to verify the presence of leishmaniasis in Tarija, sixth endemic department in Bolivia. Materials and methods: We conducted both an outbreak study (November, 1998, to December, 2002) and a longitudinal study (1997 to 2018) in humans, as well as captures of Phlebotominae and potential reservoirs.

Mass Drug Administration of Triclabendazole for in Bolivia.

Human infection with leads to obstruction of the common bile duct by adult worms and disease characterized by biliary colic, epigastric pain, and nausea. Recommended treatment is a single dose of triclabendazole (TCBZ) (10 mg/kg). Because in the 1990s the Bolivian Altiplano bordering Lake Titicaca was thought to have the highest prevalence of human fascioliasis worldwide, the Bolivian Ministry of Health instituted TCBZ mass drug administration (MDA).